These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16533131)

  • 1. Treatment of anxiety disorders with venlafaxine XR.
    Thase ME
    Expert Rev Neurother; 2006 Mar; 6(3):269-82. PubMed ID: 16533131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.
    Pae CU; Lim HK; Ajwani N; Lee C; Patkar AA
    Expert Rev Neurother; 2007 Jun; 7(6):603-15. PubMed ID: 17563244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The patient with comorbid depression and anxiety: the unmet need.
    Bakish D
    J Clin Psychiatry; 1999; 60 Suppl 6():20-4. PubMed ID: 10235121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
    Pollack MH; Meoni P; Otto MW; Simon N; Hackett D
    J Clin Psychopharmacol; 2003 Jun; 23(3):250-9. PubMed ID: 12826987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
    Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
    Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine in the treatment of anxiety disorders.
    Katzman M
    Expert Rev Neurother; 2004 May; 4(3):371-81. PubMed ID: 15853535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.
    Klein E
    J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of depression with different formulations of venlafaxine: a comparative analysis.
    Olver JS; Burrows GD; Norman TR
    Hum Psychopharmacol; 2004 Jan; 19(1):9-16. PubMed ID: 14716706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term goals in the management of acute and chronic anxiety disorders.
    Kjernisted KD; Bleau P
    Can J Psychiatry; 2004 Mar; 49(3 Suppl 1):51S-63S. PubMed ID: 15147036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine and generalised anxiety disorder: new preparation. Minimise recourse to drugs.
    Prescrire Int; 2001 Oct; 10(55):131-4. PubMed ID: 11824426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
    March JS; Entusah AR; Rynn M; Albano AM; Tourian KA
    Biol Psychiatry; 2007 Nov; 62(10):1149-54. PubMed ID: 17553467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.